Neuroprotection by (-)-deprenyl and related compounds

Mechanisms of Ageing and Development

Volumn 111, Issue 2-3, 1999, Pages 189-200

  Maruyama, Wakako ^a   Naoi, Makoto ^b  

^a Dept Basic Gerontology Natl I   (Japan)

^b Institute of Physical and Chemical Research   (Japan)

Author keywords

( ) Deprenyl; Aging; Anti apoptotic drug; Dopamine neurons; Parkinson's disease; Propargylamine

Indexed keywords

ALPHA TOCOPHEROL; CATALASE; CYCLOHEXIMIDE; DACTINOMYCIN; DNA; DRUG DERIVATIVE; GLUTATHIONE; LINSIDOMINE; PEROXYNITRITE; RASAGILINE; REACTIVE OXYGEN METABOLITE; SELEGILINE;

APOPTOSIS; CONFERENCE PAPER; CONTROLLED STUDY; DNA DAMAGE; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; NEUROPROTECTION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

AGING; AMPHETAMINES; ANIMALS; ANTIOXIDANTS; APOPTOSIS; CATTLE; DNA DAMAGE; DNA, NEOPLASM; INDANS; MONOAMINE OXIDASE INHIBITORS; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; NITRATES; OXIDANTS; PARKINSON DISEASE; SELEGILINE; TUMOR CELLS, CULTURED;

EID: 0032726944     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0047-6374(99)00066-4     Document Type: Conference Paper

References (31)

1. Anglade P., Vyas S., Javoy-Agid F., Herrero M.T., Michel P.P., Marquez J., Mouatt Priget A., Ruberg M., Hirsch E.C., Agid Y. A poptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12:1997;25-31.
2. Beckman J.S., Carson M., Smith C.D., Koppenol W.H. ALS, SOD, and peroxynitrite. Nature. 364:1993;584.
3. Bronzetti E., Felici L., Ferrante F., Valsecchi B. Effect of ethylene mustard aziridinium (AF64A) and of monoamine oxidase-B-inhibitor L-deprenyl on the morphology of the rat hyppocampus. Int. J. Tissue React. 14:1992;175-181.
4. Carrillo M.-C., Kanai S., Nokubo M., Ivy G.O., Sano Y., Kitani K. Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: the sex and age-related differences in the optimal dose in the rat. Exp. Neurol. 116:1992;286-294.
5. Eisler T., Teravainen H., Nelson R., Krebs H., Weise V., Lake C.R., Ebert M., Whetzel N., Murphy D., Kopin I., Calne D. Deprenyl in Parkinson's disease. Neurology. 31:1981;19-23.
6. Finberg J.P.W., Wang J., Goldstein D.S., Kopin I.J., Bankiewicz K.S. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats. J. Neurochem. 65:1995;1213-1220.
7. Finberg J.P.M., Takashima T., Johnston J.M., Commissiong J.W. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuro Rep. 9:1998;703-707.
8. Finnegan K.T., Skratt J.J., Irwin I., DeLanney L.E., Langston J.W. Protection against DSP-4 induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Eur. J. Pharmacol. 184:1990;119-126.
9. Heinonen E.H., Markku A.I., Lammintausta R.A.S. Pharmacokinetic aspects of L-deprenyl (selegiline) and its metabolises. Clin. Pharmacol. Ther. 56:1994;742-749.
10. Joseph J.A., Schukitt-Hale B., Denisova N.A., Prior R.L., Cao G., Martin A., Taglialatela G., Bickford C. Long-term dietary strawberry, spinach, or vitamin E supplementation retards the onset of age-related neuronal signal-transduction and cognitive behavioral deficits. J. Neurosci. 18:1998;8047-8055.
11. Knoll J. The pharmacology of (-)-deprenyl. J. Neural Transm. Suppl. 22:1986;75-89.
12. Maruyama W., Naoi M., Kasamatsu T., Hashizume Y., Takahashi T., Kohda K., Dostert P. An endogenous dopaminergic neurotoxin, N-methyl(R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neurochem. 69:1997;322-329.
13. Maruyama W., Takahashi T., Naoi M. (-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. J. Neurochem. 70:1998;2510-2515.
14. Mochizuki H., Goto K., Mori H., Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J. Neurol. Sci. 137:1996;120-123.
15. Mytilineou C., Radcliffe P., Leonardi K.E., Werner P., Olanow C.W. L-Deprenyl protects mesencphalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J. Neurochem. 68:1997;33-39.
16. Mytilineou C., Radcliffe P., Olanow C.W. L-(-)-Desmethylselegiline, a metabolise of selegiline, protects mesencphalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J. Neurochem. 68:1997;434-436.
17. Mytilineou C., Leonardi E.K., Radcliffe P., Heinonen E.H., Han S.-K., Cohen G., Olanow C.W. Deprenyl and desmethylselegiline protect mesencphalic neurons from toxicity induced by glutathione depletion. J. Pharm. Exp. Ther. 284:1998;700-706.
18. Olanow C.W., Hauser R.A., Gauger L., Malapira T., Koller W., Hubble J., Bushenbark K., Lilienfeld D., Esterlitz J. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann. Neurol. 38:1995;771-777.
19. Ostling O., Hohanson K.J. Microelectrophoretic study of radiation-induced DNA damage in individual mammalian cells. Biochem. Biophys. Res. Commun. 123:1984;291-298.
20. Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321:1989;1369-1371.
21. Przedborski S., Jackson-Lewis V., Yokohama R., Shibata T., Dawnson V.L., Dawnson T.M. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. USA. 93:1996;4565-4571.
22. Semkova I., Wolz P., Schilling M., Krieglstein J. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ishemic damage. Eur. J. Pharmacol. 315:1996;19-30.
23. Seniuk N.A., Henderson J.T., Tatton W.G., Roder J.C. Increased CNTF gene expression in process-bearing astrocytes following injury is augmented by R(-)-deprenyl. J. Neurosci. Res. 37:1994;278-286.
24. Tatton W.G., Greenwood C.E. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J. Neurosci. Res. 30:1991;666-672.
25. Tatton W.G., Chalmers-Redman R.M.E. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology. 47(Suppl 3):1996;S171-S183.
26. Tatton W.G., Ju W.Y.L., Holland D.P., Tai C., Kwan M. Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J. Neurochem. 63:1994;1572-1575.
27. Tetrud J.W., Langston J.W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 245:1989;519-522.
28. Wadia J.S., Chalmers-Redman R.M.E., Ju W.J.H., Carlite G.E., Phillips J.L., Frase A.D., Tatton W.G. Mitochondrial membrane potential and nuclear changes in apoptosis cased by serum and nerve growth factor withdrawal; Time course and modification by (-)-deprenyl. J. Neurosci. 18:1998;932-947.
29. Wu R.-M., Chiueh C.C., Pert A., Murphy D.L. Apparent antioxidant effect of (-)-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur. J. Pharmacol. 243:1993;241-247.
30. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease. Proc. Natl. Acad. Sci. USA. 93:1996;2696-2701.
31. Zsilla G., Foldi P., Held G., Szekely A.M., Knoll J. The effect of repeated doses of (-)-deprenyl on the dynamics of monoaminergic transmission: comparison with clorgyline. Pol. J. Pharmacol. Pharm. 38:1986;57-67.